Predictors of symptom resolution in patients with community-acquired pneumonia

Clinical Infectious Diseases

Volumn 31, Issue 6, 2000, Pages 1362-1367

  Marrie, Thomas J ^a   Lau, Catherine Y ^b   Wheeler, Susan L ^b   Wong, Cindy J ^c   Feagan, Brian G ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Janssen Ortho Inc   (Canada)

^c Queen's Cancer Research Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; OFLOXACIN;

ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMMUNICABLE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MALE; MICROBIOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTION AND FORECASTING; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OFLOXACIN; PNEUMONIA, BACTERIAL; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 0034567417     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/317495     Document Type: Article

References (17)

1. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998; 26:811-38.
2. Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. The British Thoracic Society and the Public Health Laboratory Service. Q J Med 1987;62:195-220.
3. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989;11:586-99.
4. Fine MJ, Orloff JJ, Arisumi D, et al. Prognosis of patients hospitalized with community-acquired pneumonia. Am J Med 1990;88:1-8.
5. Kapoor WN. Design of outcome studies of community-acquired pneumonia. Semin Respir Infect 1994;9:214-9.
6. Metlay JP, Fine MJ, Schulz R, et al. Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. J Gen Intern Med 1997;12:423-30.
7. Metlay JP, Atlas SJ, Borowsky LH, Singer DE. Time course of symptom resolution in patients with community-acquired pneumonia. Respir Med 1998;92:1137-42.
8. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for the treatment of community acquired pneumonia. JAMA 2000;283:749-55.
9. Lasko B, Lau CY, Saint-Pierre C, Reddington JL, Martel A, Anstey RJ. Efficacy and safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in adults: a multicentre, double-blind, randomized study. The Canadian Sinusitis Study Group. J Int Med Res 1998;26:281-91.
10. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336: 243-50.
11. Lindsted KD, Fraser GE, Steinkohl M, Beeson WL. Healthy volunteer effect in a cohort study: temporal resolution in the Adventist Health Study. J Clin Epidemiol 1996;49:783-90.
12. Etemad B. Gastrointestinal complications of renal failure. Gastroenterol Clin North Am 1998;27:875-92.
13. Field SK, Sutherland LR. Does medical antireflux therapy improve asthma in asthmatics with gastroesophageal reflux? A critical review of the literature. Chest 1998;114:275-83.
14. Hooton TM. A comparison of azithromycin and penicillin V for the treatment of streptococcal pharyngitis. Am J Med 1991;91:23-6.
15. Principi N, Esposito S. Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Saf 1999;20:25-41.
16. Langtry HD, Balfour JA. Azithromycin: a review of its use in paediatric infectious diseases. Drugs 1998;56:273-97.
17. Sackett DL. Biases in analytic research. J Chronic Dis 1979;32:51-63.